Why the study?
Omics determinants have emerged as potential innovative markers for NAFLD diagnosis and treatment, warranting an overview of pediatric NAFLD pathophysiology.
This review provides a comprehensive overview of the genetic, microbial, and omics factors contributing to the pathophysiology of pediatric NAFLD and its associated cardiometabolic risks.
Supports hypothesis generation on genetic-microbial drivers in pediatric NAFLD; leaves open prospective validation before clinical translation.
gene), an intriguing pathogenic role has also been demonstrated for the gut microbiota. More interestingly, evidence has added new factors involved in the "multiple hits" theory. In particular, omics determinants have been highlighted as potential innovative markers for NAFLD diagnosis and treatment. In fact, different branches of omics including metabolomics, lipidomics (in particular sphingolipids and ceramides), transcriptomics (including micro RNAs), epigenomics (such as DNA methylation), proteomics, and glycomics represent the most attractive pathogenic elements in NAFLD development, by providing insightful perspectives in this field. In this perspective, we aimed to provide a comprehensive overview of NAFLD pathophysiology in children, from the oldest pathogenic elements (including genetics) to the newest intriguing perspectives (such as omics branches).
No takes yet. Share an insight, caveat, or question.
Riccio et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: